Evaluating the genotoxicity of topoisomerase-targeted antibiotics

Mutagenesis

Volumn 27, Issue 3, 2012, Pages 359-365

  Smart, Daniel J ^a   Lynch, Anthony M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; GSK 299423; HISTONE H2AX; MOXIFLOXACIN; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG SCREENING; FLOW CYTOMETRY; GENE MUTATION; GENOTOXICITY; LYMPHOMA; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN TARGETING; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, NEOPLASM; BACTERIAL PROTEINS; CELL LINE, TUMOR; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; HISTONES; HUMANS; MICE; MUTAGENICITY TESTS; MUTAGENS; TOPOISOMERASE II INHIBITORS;

EID: 84860127758     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/ger089     Document Type: Article

References (43)

1. Payne, D. J., Gwynn, M. N., Holmes, D. J. and Pompliano, D. L. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov., 6, 29-40.
2. Tse-Dinh, Y. C. (2007) Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect. Disord. Drug Targets, 7, 3-9.
3. Maxwell, A. (1997) DNA gyrase as a drug target. Trends Microbiol., 5, 102-109.
4. Bradbury, B. J. and Pucci, M. J. (2008) Recent advances in bacterial topoisomerase inhibitors. Curr. Opin. Pharmacol., 8, 574-581.
5. Drlica, K., Malik, M., Kerns, R. J. and Xhao, Z. (2008) Quinolonemediated bacterial death. Antimicrob. Agents Chemother., 52, 385-392.
6. Nakada, N., Shimada, H., Hirata, T., Aoki, Y., Kamiyama, T., Watanabe, J. and Arisawa, M. (1993) Biological characterization of cyclothialidine, a new DNA gyrase inhibitor. Antimicrob. Agents Chemother., 37, 2656-2661.
7. Oblak, M., Kotnik, M. and Solmajer, T. (2007) Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr. Med. Chem., 14, 2033-2047.
8. Ostrov, D., Hernandez Prada, J. A., Corsino, P. E., Finton, K. A., Le, N. and Rowe, T. C. (2007) Discovery of novel DNA gyrase inhibitors by highthroughput virtual screening. Antimicrob. Agents Chemother., 51, 3688-3698.
9. Bax, B., Chan, P., Eggleston, D. S. et al. (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature, 466, 935-940.
10. Albertini, S., Chetelat, A. A., Miller, B., Muster, W., Pujadas, E., Strobel, R. and Gocke, E. (1995) Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic test systems. Mutagenesis, 10, 343-351.
11. Moreau, N. J., Robaux, H., Baron, L. and Tabary, X. (1990) Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II. Antimicrob. Agents Chemother., 34, 1955-1960.
12. D'Incalci, M. (1993) DNA-topoisomerase inhibitors. Curr. Opin. Oncol., 5, 1023-1028.
13. Fortune, J. M. and Osheroff, N. (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol., 64, 221-253.
14. Lynch, A., Harvey, J., Aylott, M., Nicholas, E., Burman, M., Siddiqui, A., Walker, S. and Rees, R. (2003) Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. Mutagenesis, 18, 345-353.
15. Muller, L. and Kasper, P. (2000) Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutat. Res., 464, 19-34.
16. Custer, L. L. and Sweder, K. S. (2008) The role of genetic toxicology in drug discovery and optimization. Curr. Drug Metab., 9, 978-985.
17. Smart, D. J., Ahmedi, K. P., Harvey, J. S. and Lynch, A. M. (2011) Genotoxicity screening via the cH2AX by flow assay. Mutat. Res., 715, 25-31.
18. Smart, D. J. (2008) Genotoxicity of topoisomerase II inhibitors: an antiinfective perspective. Toxicology, 254, 192-198.
19. Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S. and Pommier, Y. (2008) GammaH2AX and cancer. Nat. Rev. Cancer, 8, 957-967.
20. Kinner, A., Wu, W., Staudt, C. and Iliakis, G. (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acid Res., 36, 5678-5694.
21. Smart, D. J., Halicka, H. D., Schmuck, G., Traganos, F., Darzynkiewicz, Z. and Williams, G. M. (2008) Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone. Mutat. Res., 641, 43-47.
22. MacPhail, S. H., Banath, J. P., Yu, T. Y., Chu, E. H., Lambur, H. and Olive, P. L. (2003) Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int. J. Radiat. Biol., 79, 351-358.
23. Banath, J. P. and Olive, P. L. (2003) Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res., 63, 4347-4350.
24. Halicka, H. D., Ozkaynak, M. F., Levendoglu-Tugal, O., Sandoval, C., Seiter, K., Kajstura, M., Traganos, F., Jayabose, S. and Darzynkiewicz, Z. (2009) DNA damage response as a biomarker in treatment of leukemias. Cell Cycle, 8, 1720-1724.
25. Qvarnstrom, O. F., Simonsson, M., Johansson, K. A., Nyman, J. and Turesson, I. (2004) DNA double strand break quantification in skin biopsies. Radiother. Oncol., 72, 311-317.
26. Kurose, A., Tanaka, T., Huang, X., Halicka, H. D., Traganos, F., Dai, W. and Darzynkiewicz, Z. (2005) Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis. Cytometry A, 68, 1-9.
27. Huang, X., Traganos, F. and Darzynkiewicz, Z. (2003) DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis. Cell Cycle, 2, 614-619.
28. Huang, X., Halicka, H. D., Traganos, F., Tanaka, T., Kurose, A. and Darzynkiewicz, Z. (2005) Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis. Cell Prolif., 38, 223-243.
29. Clive, D., Flamm, W. G., Machesko, M. R. and Bernheim, N. J. (1972) A mutational assay system using the thymidine kinase locus in mouse lymphoma cells. Mutat. Res., 16, 77-87.
30. Moore, M. M., Honma, M., Clements, J. et al. (2006) Mouse lymphoma thymidine kinase gene mutation assay: follow-up meeting of the International Workshop on Genotoxicity Testing-Aberdeen, Scotland, 2003-assay acceptance criteria, positive controls, and data evaluation. Environ. Mol. Mutagen., 47, 1-5.
31. Moore, M. M., Honma, M., Clements, J. et al. (2007) Mouse lymphoma thymidine kinase gene mutation assay: meeting of the International Workshop on Genotoxicity Testing. San Francisco, 2005, recommendations for 24-h treatment. Mutat. Res., 627, 36-40.
32. Downes, C. S., Clarke, D. J., Mullinger, A. M., Gimenez-Abian, J. F., Creighton, A. M. and Johnson, R. T. (1994) A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature, 372, 467-470.
33. Larsen, A. K., Escargueil, A. E. and Skladanowski, A. (2003) From DNA damage to G2 arrest: the many roles of topoisomerase II. Prog. Cell Cycle Res., 5, 295-300.
34. Ashby, J., Tinwell, H., Glover, P., Allen-Poorman, P., Krehl, R., Callander, R. D. and Clive, D. (1994) Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: comparison to Salmonella responses. Environ. Mol. Mutagen., 24, 51-60.
35. Backer, L. C., Allen, J. W., Brock-Harrington, K., Campbell, J. A., DeMarini, D. M., Doerr, C. L., Howard, D. R., Kligerman, A. D. and Moore, M. M. (1990) Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro. Mutagenesis, 5, 541-547.
36. Sappal, D. S., McClendon, A. K., Fleming, J. A. et al. (2004) Biological characterization of MLN944: a potent DNA binding agent. Mol. Cancer Ther., 3, 47-58.
37. Goodell, J. R., Ougolkov, A. V., Hiasa, H., Kaur, H., Remmel, R., Billadeau, D. D. and Ferguson, D. M. (2008) Acridine-based agents with topoisomerase II activity inhibit pancreatic cancer cell proliferation and induce apoptosis. J. Med. Chem., 51, 179-182.
38. Boos, G. and Stopper, H. (2000) Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol. Lett., 116, 7-16.
39. Errington, F., Willmore, E., Leontiou, C., Tilby, M. J. and Austin, C. A. (2004) Differences in the longevity of topo IIalpha and topo IIbeta drugstabilized cleavable complexes and the relationship to drug sensitivity. Cancer Chemother. Pharmacol., 53, 155-162.
40. Perrin, D., van Hille, B. and Hill, B. T. (1998) Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents. Biochem. Pharmacol., 56, 503-507.
41. Rene, B., Fosse, P., Khelifa, T., Jacquemin-Sablon, A. and Bailey, C. (1996) The 1#-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity. Mol. Pharmacol., 49, 343-350.
42. Caron, P. R. (1999) Compendium of DNA topoisomerase sequences. Methods Mol. Biol., 94, 279-316.
43. Eot-Houllier, G., Fulcrand, G., Magnaghi-Jaulin, L. and Jaulin, C. (2009) Histone deacetylase inhibitors and genomic instability. Cancer Lett., 274, 169-176.